BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27044543)

  • 21. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
    Pane F; Cimino G; Izzo B; Camera A; Vitale A; Quintarelli C; Picardi M; Specchia G; Mancini M; Cuneo A; Mecucci C; Martinelli G; Saglio G; Rotoli B; Mandelli F; Salvatore F; Foà R;
    Leukemia; 2005 Apr; 19(4):628-35. PubMed ID: 15744351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
    Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zuo Z; Jones D; Yao H; Thomas DA; O'Brien S; Ravandi F; Kantarjian HM; Abruzzo LV; Medeiros LJ; Chen SS; Luthra R
    Mod Pathol; 2010 Nov; 23(11):1524-34. PubMed ID: 20729815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors and outcome of therapy in adult acute lymphoblastic leukemia.
    Philips GK; Crowell EB; Mani A
    Indian J Cancer; 1991 Sep; 28(3):148-54. PubMed ID: 1786981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
    Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
    Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.
    Sun D; Elson P; Liedtke M; Medeiros BC; Earl M; Alizadeh A; Bates J; Sekeres MA; Coutre S; Kalaycio M; Sobecks R; Copelan E; Advani AS
    Am J Hematol; 2012 Oct; 87(10):957-60. PubMed ID: 22729847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
    Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
    Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
    Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
    Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
    Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome.
    Abaza HM; Elmougy MI; El Maraghy HM; Mahmoud HM
    Int J Lab Hematol; 2016 Feb; 38(1):81-9. PubMed ID: 26547904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
    Fu MW; Mi YC; Qiu LG; Yu WJ; Lin D; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):435-40. PubMed ID: 19035173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial.
    Hunault M; Truchan-Graczyk M; Caillot D; Harousseau JL; Bologna S; Himberlin C; Guyotat D; Berthou C; Casassus P; Baranger L; Béné MC; Ifrah N; Gyan E;
    Haematologica; 2007 Dec; 92(12):1623-30. PubMed ID: 18055985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical features and prognosis of children with lymphoblastic lymphoma].
    Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses.
    Szczepanek J; Styczyński J; Haus O; Tretyn A; Wysocki M
    Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):61-8. PubMed ID: 21246408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
    Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
    Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.